PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $3.38B
1-Year Est. Return 58.81%
This Quarter Est. Return
1 Year Est. Return
+58.81%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$3.38B
AUM Growth
+$1.04B
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
39
New
Increased
Reduced
Closed

Top Buys

1
+$133M
2
+$117M
3
+$92M
4
URGN icon
UroGen Pharma
URGN
+$84.1M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$61.5M

Top Sells

1
+$103M
2
+$84.2M
3
+$63.7M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$41.5M
5
LENZ
LENZ Therapeutics
LENZ
+$30M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EYPT icon
26
EyePoint Inc
EYPT
$1.25B
$28.6M 0.81%
+2,005,365
TNGX icon
27
Tango Therapeutics
TNGX
$1.75B
$25.9M 0.74%
+3,086,184
AMLX icon
28
Amylyx Pharmaceuticals
AMLX
$1.57B
$25.8M 0.73%
+1,900,000
SYRE icon
29
Spyre Therapeutics
SYRE
$2.58B
$24.6M 0.7%
1,467,266
-403,179
DYN icon
30
Dyne Therapeutics
DYN
$2.75B
$24M 0.68%
+1,898,950
BBOT
31
BridgeBio Oncology
BBOT
$913M
$21.6M 0.61%
+1,866,141
IRON icon
32
Disc Medicine
IRON
$2.68B
$16.4M 0.47%
247,716
-963,255
GPCR icon
33
Structure Therapeutics
GPCR
$6.26B
$10.4M 0.3%
+372,869
IMTX icon
34
Immatics
IMTX
$1.32B
– –
-3,144,157
MLTX icon
35
MoonLake Immunotherapeutics
MLTX
$1.19B
– –
-878,323
XBI icon
36
State Street SPDR S&P Biotech ETF
XBI
$8.67B
– –
0
YMAB
37
DELISTED
Y-mAbs Therapeutics
YMAB
– –
-4,236,346
CBIO
38
Crescent Biopharma
CBIO
$411M
– –
-642,721
ONC
39
BeOne Medicines Ltd
ONC
$37.4B
– –
-347,787
1
2